A novel double-targeted nondrug delivery system for targeting cancer stem cells

Shupei Qiao,1,* Yufang Zhao,1,* Shuai Geng,2,* Yong Li,1,* Xiaolu Hou,1,3 Yi Liu,1 Feng-Huei Lin,4,5 Lifen Yao,6 Weiming Tian1 1School of Life Science and Technology, Harbin Institute of Technology, 2Department of Pharmacology, Harbin Medical University, 3Department of Cardiology, The Fourth Affili...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Qiao S, Zhao Y, Geng S, Li Y, Hou X, Liu Y, Lin FH, Yao L, Tian W
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Nanoparticles Cancer stem cell PEG-PLGA DCLK1 Hyaluronic acid Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/158b4009e4324e2bb7273edf743d1506
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:158b4009e4324e2bb7273edf743d1506
record_format	dspace
spelling	oai:doaj.org-article:158b4009e4324e2bb7273edf743d15062021-12-02T05:10:45ZA novel double-targeted nondrug delivery system for targeting cancer stem cells1178-2013https://doaj.org/article/158b4009e4324e2bb7273edf743d15062016-12-01T00:00:00Zhttps://www.dovepress.com/a-novel-double-targeted-nondrug-delivery-system-for-targeting-cancer-s-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Shupei Qiao,1,* Yufang Zhao,1,* Shuai Geng,2,* Yong Li,1,* Xiaolu Hou,1,3 Yi Liu,1 Feng-Huei Lin,4,5 Lifen Yao,6 Weiming Tian1 1School of Life Science and Technology, Harbin Institute of Technology, 2Department of Pharmacology, Harbin Medical University, 3Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China; 4Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan; 5Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli, Taiwan; 6Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China *These authors contributed equally to this work Abstract: Instead of killing cancer stem cells (CSCs), the conventional chemotherapy used for cancer treatment promotes the enrichment of CSCs, which are responsible for tumor growth, metastasis, and recurrence. However, most therapeutic agents are only able to kill a small proportion of CSCs by targeting one or two cell surface markers or dysregulated CSC pathways, which are usually shared with normal stem cells (NSCs). In this study, we developed a novel nondrug delivery system for the dual targeting of CSCs by conjugating hyaluronic acid (HA) and grafting the doublecortin-like kinase 1 (DCLK1) monoclonal antibody to the surface of poly(ethylene glycol) (PEG)–poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs), which can specifically target CD44 receptors and the DCLK1 surface marker – the latter was shown to possess the capacity to distinguish between CSCSs and NSCs. The size and morphology of these NPs were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). This was followed by studies of NP encapsulation efficiency and in vitro drug release properties. Then, the cytotoxicity of the NPs was tested via Cell Counting Kit-8 assay. Finally, the 4T1 CSCs were obtained from the alginate-based platform, which we developed as an in vitro tumor model. Tumor-bearing nude mice were used as in vivo models to systematically detect the ability of NPs to target CSCs. Our results showed that the DCLK1–HA–PEG–PLGA NPs exhibited a targeting effect toward CSCs both in vitro and in vivo. These findings have important implications for the rational design of drug delivery systems that target CSCs with high efficacy. Keywords: alginate, CD44, PEG–PLGA, DCLK1, hyaluronic acidQiao SZhao YGeng SLi YHou XLiu YLin FHYao LTian WDove Medical PressarticleNanoparticlesCancer stem cellPEG-PLGADCLK1Hyaluronic acidMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 11, Pp 6667-6678 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Nanoparticles Cancer stem cell PEG-PLGA DCLK1 Hyaluronic acid Medicine (General) R5-920
spellingShingle	Nanoparticles Cancer stem cell PEG-PLGA DCLK1 Hyaluronic acid Medicine (General) R5-920 Qiao S Zhao Y Geng S Li Y Hou X Liu Y Lin FH Yao L Tian W A novel double-targeted nondrug delivery system for targeting cancer stem cells
description	Shupei Qiao,1,* Yufang Zhao,1,* Shuai Geng,2,* Yong Li,1,* Xiaolu Hou,1,3 Yi Liu,1 Feng-Huei Lin,4,5 Lifen Yao,6 Weiming Tian1 1School of Life Science and Technology, Harbin Institute of Technology, 2Department of Pharmacology, Harbin Medical University, 3Department of Cardiology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China; 4Institute of Biomedical Engineering, National Taiwan University, Taipei, Taiwan; 5Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli, Taiwan; 6Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, People’s Republic of China *These authors contributed equally to this work Abstract: Instead of killing cancer stem cells (CSCs), the conventional chemotherapy used for cancer treatment promotes the enrichment of CSCs, which are responsible for tumor growth, metastasis, and recurrence. However, most therapeutic agents are only able to kill a small proportion of CSCs by targeting one or two cell surface markers or dysregulated CSC pathways, which are usually shared with normal stem cells (NSCs). In this study, we developed a novel nondrug delivery system for the dual targeting of CSCs by conjugating hyaluronic acid (HA) and grafting the doublecortin-like kinase 1 (DCLK1) monoclonal antibody to the surface of poly(ethylene glycol) (PEG)–poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles (NPs), which can specifically target CD44 receptors and the DCLK1 surface marker – the latter was shown to possess the capacity to distinguish between CSCSs and NSCs. The size and morphology of these NPs were characterized by dynamic light scattering (DLS), transmission electron microscopy (TEM), and scanning electron microscopy (SEM). This was followed by studies of NP encapsulation efficiency and in vitro drug release properties. Then, the cytotoxicity of the NPs was tested via Cell Counting Kit-8 assay. Finally, the 4T1 CSCs were obtained from the alginate-based platform, which we developed as an in vitro tumor model. Tumor-bearing nude mice were used as in vivo models to systematically detect the ability of NPs to target CSCs. Our results showed that the DCLK1–HA–PEG–PLGA NPs exhibited a targeting effect toward CSCs both in vitro and in vivo. These findings have important implications for the rational design of drug delivery systems that target CSCs with high efficacy. Keywords: alginate, CD44, PEG–PLGA, DCLK1, hyaluronic acid
format	article
author	Qiao S Zhao Y Geng S Li Y Hou X Liu Y Lin FH Yao L Tian W
author_facet	Qiao S Zhao Y Geng S Li Y Hou X Liu Y Lin FH Yao L Tian W
author_sort	Qiao S
title	A novel double-targeted nondrug delivery system for targeting cancer stem cells
title_short	A novel double-targeted nondrug delivery system for targeting cancer stem cells
title_full	A novel double-targeted nondrug delivery system for targeting cancer stem cells
title_fullStr	A novel double-targeted nondrug delivery system for targeting cancer stem cells
title_full_unstemmed	A novel double-targeted nondrug delivery system for targeting cancer stem cells
title_sort	novel double-targeted nondrug delivery system for targeting cancer stem cells
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/158b4009e4324e2bb7273edf743d1506
work_keys_str_mv	AT qiaos anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT zhaoy anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT gengs anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT liy anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT houx anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT liuy anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT linfh anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT yaol anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT tianw anoveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT qiaos noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT zhaoy noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT gengs noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT liy noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT houx noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT liuy noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT linfh noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT yaol noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells AT tianw noveldoubletargetednondrugdeliverysystemfortargetingcancerstemcells
_version_	1718400514829320192

A novel double-targeted nondrug delivery system for targeting cancer stem cells

Ejemplares similares